Brokers Issue Forecasts for Compugen FY2025 Earnings

Compugen Ltd. (NASDAQ:CGEN) – HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Compugen in a research report issued to clients and investors on Wednesday, January 7th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will earn $0.37 per share for the year. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Compugen’s Q4 2025 earnings at $0.56 EPS and FY2026 earnings at ($0.35) EPS.

A number of other analysts also recently issued reports on CGEN. Wall Street Zen raised Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.00.

Compugen Trading Up 14.6%

Shares of CGEN stock opened at $1.88 on Friday. The firm’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $1.58. Compugen has a 1 year low of $1.13 and a 1 year high of $2.66. The firm has a market capitalization of $146.35 million, a P/E ratio of -6.27 and a beta of 2.85.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.47 million. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%.

Institutional Trading of Compugen

Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. grew its stake in Compugen by 51.0% in the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 34,215 shares during the last quarter. Two Sigma Investments LP lifted its position in Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Jane Street Group LLC increased its stake in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares during the period. Finally, Franklin Resources Inc. bought a new position in shares of Compugen during the second quarter worth approximately $56,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.